Hengrui Pharma granted IND (Investigational New Drug) approvals for four drug candidates
January 12, 2026
Source: drugdu
45
Beijing Business Today — On Jan. 9, Jiangsu Hengrui Pharmaceuticals Co., Ltd. released an announcement stating that the company and its subsidiaries (Chengdu Shengdi Pharma and Shanghai Hengrui Pharma) have obtained IND (Investigational New Drug) approvals from the NMPA for SHR-4394 (for injection), HRS-5041 tablets, Zemetostat (SHR-2554), and Rezvilutamide. The upcoming clinical program features a multicenter, open-label Phase II trial investigating SHR-4394 or HRS-5041 combined with anti-tumor therapies for the treatment of prostate cancer, focusing on safety, tolerability, and efficacy.
https://finance.eastmoney.com/a/202601093614353893.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- NVIDIA and Eli Lilly jointly invested 1 billion US dollars to establish an AI drug research laboratory January 13, 2026
- 3D Medicines’ innovative drug Envita has been accepted by the National Medical Products Administration for marketing approval for first-line treatment of biliary tract cancer. January 13, 2026
- Haixiang Pharmaceutical and Wanbangde Pharmaceutical signed an innovative drug cooperation agreement focusing on the research and development of orphan drugs for ALS. January 13, 2026
- China’s dual-resistance technology is on a roll! Rongchang RC148 secures a $5.6 billion order from AbbVie January 13, 2026
- The marketing application of CSPC Pharmaceutical Group’s pulgliptin metformin extended-release tablets has been accepted by the National Medical Products Administration. January 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
